WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

bioAffinity Technologies (Nasdaq:BIAF) priced a registered public offering for expected gross proceeds of $3.2 million before fees and expenses.

Rhea-AI Summary

bioAffinity Technologies (Nasdaq:BIAF) priced a registered public offering for expected gross proceeds of $3.2 million before fees and expenses.

The deal comprises 4,000,000 shares of common stock (or pre-funded warrants) at $0.80 per share, with closing anticipated around June 18, 2026. WallachBeth Capital is sole placement agent.

Positive

• Raises approximately $3.2 million in gross proceeds before fees
• Registered offering under effective Form S-1 (File No. 333-296764)
• Engages WallachBeth Capital as sole placement agent for the transaction

Negative

• Issuance of 4,000,000 new shares may dilute existing shareholders
• Offering price of $0.80 per share may signal pressure on valuation

Argus Jun 17 session

-11.96% close to close Open Argus

Details

News Market Reaction – BIAF

On Jun 17, the day this news came out, BIAF closed 11.96% below the previous close.

Data tracked by StockTitan Argus for the Jun 17 session.

Key Figures

Gross proceeds: $3.2 million Shares offered: 4,000,000 shares Offering price per share: $0.80 per share +5 more

Gross proceeds

$3.2 million

Aggregate gross proceeds from current public offering

Shares offered

4,000,000 shares

Common stock (or pre-funded warrants) in current offering

Offering price per share

$0.80 per share

Purchase price for common stock in offering

Pre-funded warrant price

$0.793 per warrant

Purchase price per pre-funded warrant in offering

Par value

$0.007 per share

Par value of common stock underlying offering

Expected closing date

June 18, 2026

Expected closing of the public offering

Registration statement

Form S-1, File No. 333-296764

SEC registration statement for this offering

Price reaction

-31.04%

Share price move ahead of / around offering news

Previous Offering Reports

4 past events · Latest: Sep 30

Same Type 4 events

1. Sep 30

   Public offering closing

   24h Move

   -8.9%

   Closed $4.8M public offering of common stock and pre-funded warrants.

2. Sep 30

   Offering completion

   24h Move

   -8.9%

   Announced completion of $4.8M public offering to raise gross proceeds.

3. Sep 29

   Offering pricing

   24h Move

   -8.9%

   Priced $4.8M public offering with common stock or pre-funded warrants.

4. Sep 29

   Offering pricing

   24h Move

   -38.6%

   Announced pricing of $4.8M public offering of common stock and warrants.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

pre-funded warrants, registration statement on Form S-1, prospectus, placement agent

4 terms

pre-funded warrants financial

"The offering consists of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof)..."

Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.

registration statement on Form S-1 regulatory

"The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-296764)..."

A registration statement on Form S-1 is a detailed filing a company submits to the U.S. securities regulator to register new shares for public sale; it includes a plain-language prospectus, financial statements, business description and risk factors. For investors it matters because it provides the official, comprehensive blueprint of the offering — like an owner’s manual — allowing buyers to assess risks, inspect financial health and compare valuation before deciding to invest.

prospectus regulatory

"The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement."

A prospectus is a detailed document that explains a company's plans for offering new shares or investments to the public. It’s important because it provides potential investors with key information about the company’s business, risks, and how they might make money, helping them decide whether to invest. Think of it as a guidebook for understanding what you're buying into.

placement agent financial

"WallachBeth Capital, LLC is acting as sole placement agent for the offering."

A placement agent is a professional or firm that helps organizations raise money from investors, such as individuals, institutions, or funds. They act like matchmakers, connecting those seeking investments with the right investors and guiding the process to ensure successful funding. For investors, they can provide access to exclusive opportunities and help navigate complex fundraising efforts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

JERSEY CITY, N.J., June 17, 2026 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases, priced a Public Offering of securities as described below for aggregate gross proceeds to the Company of $3.2 million, before deducting agent fees and other estimated expenses payable by the company.

The offering consists of 4,000,000 shares of its common stock, par value $0.007 per share (or pre-funded warrants in lieu thereof) at a purchase price of $0.80 per share (or $0.793 per pre-funded warrant). Each pre-funded warrant will be exercisable for one share of common stock and will be immediately exercisable and will expire when exercised in full.

The closing of the offering is expected to occur on or about June 18, 2026, subject to the satisfaction of customary closing conditions.

WallachBeth Capital, LLC is acting as sole placement agent for the offering.

The securities described above are being offered by the Company pursuant to a registration statement on Form S-1 (File No. 333-296764), as amended, previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction. The offering is being made only by means of a preliminary prospectus and final prospectus that will form a part of the registration statement. A final prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at www.sec.gov. Electronic copies of the prospectus supplements may be obtained, when available, from WallachBeth Capital, LLC, via email at cap-mkts@wallachbeth.com, by calling +1 (646) 237-8585, or by standard mail at WallachBeth Capital LLC, Attn: Capital Markets, 185 Hudson St., Suite 1410, Jersey City, NJ 07311, USA.

About WallachBeth Capital LLC:

WallachBeth Capital offers a robust range of capital markets and investment banking services to the healthcare community, connecting corporate clients with leading institutions, supporting issuers and investors in achieving their financial goals. The firm's experience includes initial public offerings, follow-on issues, PIPE offerings, and private transactions and ATM's.

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Words such as "may," "might," "will," "should," "believe," "expect," "anticipate," "estimate," "continue," "predict," "forecast," "project," "plan," "intend" or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, the Company's ability to close the offering when anticipated and the risk factors discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2025, and its subsequent filings with the SEC, including subsequent periodic reports on Forms 10-Q and 8-K. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. While the Company believes these forward-looking statements are reasonable, readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The information in this release is provided only as of the date of this release, and the Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

View original content:https://www.prnewswire.com/news-releases/wallachbeth-capital-announces-pricing-of-bioaffinity-technologies-3-2-million-offering-302803249.html

SOURCE WallachBeth Capital LLC

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did bioAffinity Technologies (BIAF) announce about its June 2026 stock offering?

bioAffinity Technologies announced a registered public offering expected to raise about $3.2 million in gross proceeds. According to bioAffinity Technologies, the deal includes common stock or pre-funded warrants, with WallachBeth Capital acting as sole placement agent under an effective Form S-1 registration.

How many shares are included in the new bioAffinity Technologies (NASDAQ:BIAF) offering and at what price?

The offering includes 4,000,000 shares of common stock, or pre-funded warrants in lieu, priced at $0.80 per share. According to bioAffinity Technologies, each pre-funded warrant costs $0.793, is immediately exercisable for one share, and remains outstanding until fully exercised.

When is the closing date for the bioAffinity Technologies (BIAF) $3.2 million offering?

The closing of the offering is expected on or about June 18, 2026, subject to customary conditions. According to bioAffinity Technologies, completion depends on standard closing requirements typically applied to registered public offerings conducted under an effective Securities and Exchange Commission Form S-1 registration statement.

What type of securities is bioAffinity Technologies (BIAF) issuing in its June 2026 offering?

bioAffinity Technologies is issuing common stock and pre-funded warrants in its June 2026 offering. According to bioAffinity Technologies, each pre-funded warrant is immediately exercisable for one share of common stock and remains outstanding until exercised in full, providing an alternative to directly purchasing shares.

Who is acting as placement agent for the bioAffinity Technologies (BIAF) June 2026 offering?

WallachBeth Capital is serving as sole placement agent for the offering. According to bioAffinity Technologies, WallachBeth Capital is coordinating the transaction, with the securities registered on Form S-1 and the related final prospectus to be filed and available on the SEC website.

How can investors access the prospectus for the bioAffinity Technologies (BIAF) $3.2 million offering?

Investors can access the final prospectus on the SEC website once filed. According to bioAffinity Technologies, electronic copies may also be requested from WallachBeth Capital via email, phone, or standard mail through its Capital Markets group in Jersey City, New Jersey.